Novo Nordisk and Ginkgo Bioworks Join Forces for Mass Production of Therapies and Innovations
Monday, 15 April 2024, 14:00
Massive manufacturing needs will require novel manufacturing solutions
The new strategic partnership between Novo Nordisk and Ginkgo will cover five years, and it builds upon an earlier and much smaller collaboration program.
This time, the focus will be on manufacturing therapies for chronic diseases, including drugs that are competing in core segments for Novo Nordisk, like diabetes and obesity medications.
Impacts on Novo Nordisk
- High demand for their blockbuster diabetes drugs
- Continuous research and development activities to enhance product benefits
Risks of Investing in Ginkgo
- Small biotech with uncertain revenue growth
- Dependency on unproven manufacturing services
Buying one of these stocks is a risky move right now.
Novo Nordisk stock is ready to buy today, but investing in Ginkgo should be approached with caution.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.